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Abstract
Purpose: Vascular cell adhesion molecule-1 (VCAM1) is a transmembraneglycoprotein, which is expressed on endothelium and plays role in inflammation. Itis over-expressed on colorectal cancer (CRC) cells and plays role in metastasisdevelopment and angiogenesis. We aimed to compare serum VCAM1 levels of CRCpatients with heathy controls and evaluate its relationship with clinicopathologicalparameters, treatment response and overall survival (OS). Methods: The studyenrolled 111 patients with histopathologically confirmed CRC followed-up in ourclinic and 30 sex- and age-matched healthy controls. Pre-treatment serum VCAM1levels were determined by the solid-phase sandwich ELISA method. Results:Metastatic disease was present in 57 patients. Forty percent of 40 metastaticpatients receiving systemic therapy had partial or complete response. The medianserum VCAM1 level was significantly higher in CRC patients than controls(p<0.001). In addition, serum VCAM1 level was significantly higher in diabetic CRCpatients than those without diabetes (p = 0.03). There was no significantrelationship between VCAM1 and other clinicopathological parameters includingstage and response to systemic therapy. The median follow-up period was 12(±8.2) months. Twenty patients were dead at the time of analysis. The presence ofmetastasis (p < 0.001) and elevated CEA level (p < 0.001) were factors affecting OSsignificantly. However, serum VCAM1 did not have a significant impact on OS (p =0.55). Conclusion: Serum VCAM1 level is significantly elevated in CRC patientsregardless of the tumor stage. However, it has no prognostic or predictive role forresponse to systemic therapy.
Keywords: Colorectal Cancer; Serum VCAM1; Survival
1. IntroductionCarcinogenesis and metastasis development aremulti-step processes which require the interaction ofendothelium and tumor cells. Adhesion molecules playan important role in this interaction. Vascular celladhesion molecule-1 (VCAM1) is a transmembraneglycoprotein from the immunoglobulin superfamily,which is expressed on activated endothelium and
contributes in leukocyte adhesion and extravasationduring inflammation.1,2 VCAM1, which acts as a ligand ofVLA-4 ( α4β1 integrin), is also expressed on proximalrenal tubuli and dentritic cells.1VCAM1 is thought to be involved in inflammatoryresponse against the tumor but also in metastasis
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development and angiogenesis.3,4 Inflammatorycytokines and reactive oxygen species are the maininducers of endothelial VCAM1 expression and blockageof VCAM1 inhibits leukocyte extravasation andinflammation.1,5 It has been demonstrated that VCAM1expression is decreased on endothelium infiltrated bytumor cells, inside the lung metastasis site of melanomaand carcinoma cells in vivo.6 Tumor may decreaseVCAM1 expression on vessels of metastatic sites,prevent extravasation of cytotoxic T lymphocytes intothe tumor and consequently escape from the immunsystem.6Fifty seven percent of colorectal cancer (CRC) patientshave elevated VCAM1 mRNA level in CRC tissuecompared to normal tissue around the tumor.7 Theintensity of VCAM1 staining on tumor vessels is alsoassociated with increased T lymphocyte infiltration,suggesting that VCAM1 over-expression may play role inanti-tumor immunity of the host via T lymphocytes.7Vessels surrounding CRC tissue over-express VCAM1.Vascular endothelial growth factor (VEGF) and cytokinessecreted by tumor cell, such as tumor necrosis factoralpha (TNF-α), interferon-gamma (IFN-γ) andinterleukin-1(IL-1) induce VCAM1 expression5,7,8, whichfacilitates metastasis development in vitro.2,3 Besides,presence of soluble VCAM1 has been shown in both CRCand activated endothelial cells.2,7 Secretion of VCAM1from endothelium activated by leukocyte adhesion mayinduce chemotaxis of endothelial cells suggesting therole of VCAM1 in neovascularization.9Levels of circulating adhesion molecules are elevated inmany inflammatory and malignant diseases associatedwith endothelial activation. However, few studiesrevealed the relationship between the level of thesemolecules and tumor behavior.1,2,10-14 It has been shownthat blood VCAM1 level is elevated in some solid tumors,such as breast, ovary, bladder, pancreas, gastric andhead and neck carcinoma.10,12,14-17 In addition, bloodVCAM1 level is associated with disease stage and poorprognosis and may decrease with anti-cancer treatmentin different solid tumor types.10,12,14,15,17-19Revealing serum VCAM1 level of CRC patients and itsrelationship with other clinicopathological parameters,treatment response and survival may improveindividual treatment strategies and provide a betterunderstanding of the pathogenesis of the disease. Fewstudies have addressed the clinical significance ofcirculating VCAM1 level in CRC and these studiesincluded very heterogeneous patient groups,unfortunately.2,3,11,20-23 In addition, conflicting resultshave been obtained about serum VCAM1 level and itsrelationship with tumor burden and prognosis.2,3,11,20-23In the current study, we aimed to compare serumVCAM1 levels of CRC patients with healthy controls andevaluate its relationship with clinicopathological
parameters, treatment response and overall survival(OS).
2. Methods and Materials
2.1 PatientsThis study included 111 patients withhistopathologically confirmed colon or rectal carcinomawho were treated and followed-up between February2010 and September 2013, in Istanbul University,Institute of Oncology. In addition, 30 sex- andage-matched healthy controls were included in theserum VCAM1 analysis for comparison. Tumor staging(TNM classification) was performed according to theAmerican Joint Committee on Cancer (AJCC) stagingsystem (7th edition). Informed consent was obtainedfrom all patients and the study was reviewed andapproved by our local ethical committee.Clinical (age, gender, date of diagnosis, stage, smokingstatus, comorbidities, body mass index (BMI), ECOG(Eastern Cooperative Oncology Group) performancescore (PS), treatment modalities and responses, laststatus  (progression/exitus)), laboratory (pretreatmentserum CEA and CA19.9 levels) and histopathological(angiolymphatic invasion (ALI), venous invasion (VI),perineural invasion (PNI), grade, KRAS status (formetastatic patients), regression score (for rectum cancerpatients who received neoadjuvant radiotherapy)) datawere obtained from medical charts of patients. Patientswere treated and followed-up according to acceptedinternational treatment guidelines, taking their tumorstages, PS, comorbidities and preferences into account.RECIST (Response Evaluation Criteria In Solid Tumors)criteria were used to evaluate response to systemictherapy in metastatic patients. Those with complete orpartial responses were considered as responsive tosystemic therapy.
2.2 Measurement of serum VCAM1 levelsBlood samples were obtained from the CRC patients andhealthy controls (n = 30) by venipuncture and clotted atroom temperature. The blood samples of early stagepatients were taken within 30 days after surgery andwithin 14 days before adjuvant therapy. For metastaticpatients, blood samples were obtained within 14 daysbefore systemic therapy.The sera were collected following centrifugation andfrozen immediately at -20°C until analysis. SerumVCAM1 (eBioscience, Austria) levels were determinedby the solid-phase sandwich ELISA method.The VCAM1 ELISA (eBioscience, Austria) uses a double-antibody sandwich enzyme-linked immunosorbentassay to determine the level of Human Vascular CellAdhesion Molecule-1 (VCAM1) in samples. Serumsamples and standards are added to the wells which arepre-coated with Human VCAM1 monoclonal antibody.
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Biotin-conjugated anti-human VCAM1 antibody andStreptavidin-HRP is added. Biotin-conjugated anti-human VCAM1 antibody binds to human VCAM1captured by the first antibody. Streptavidin-HRP bindsto the biotin-conjugated anti-human VCAM1 antibody.Following incubation unbound Streptavidin-HRP isremoved during a wash step, and substrate solutionreactive with HRP is added to the wells. A coloredproduct is formed in proportion to the amount of humanVCAM1 present in the sample or standard. The reactionis terminated by an addition of acid (stop solution) andabsorbance is measured using an automated ELISAreader (Rayto, RT-1904C Chemistry Analyzer, AtlantaGA, USA) at wavelenght of 450±10 nm. The results wereexpressed as ng/mL.
2.3 Statistical analysisComparisons of numerical variables including serumVCAM1 levels in CRC patients and controls, in additionto patient subgroups according to various clinical/pathological/laboratory parameters were carried outusing the independent samples t test for normallydistributing groups and the Mann–Whitney U test fornon-normally distributing groups. Comparisons ofnumerical variables between multiple groups wereperformed by using One –Way Anova test for normallydistributing groups and Kruskal-Wallis test fornon-normally distributing groups. While investigatingthe associations between serum VCAM1, CEA, CA19.9and BMI, Spearman or Pearson tests were used forcalculation of correlation coefficients and theirsignificance. Overall survival (OS) was calculated fromthe date of venous blood sampling to death resultingfrom any cause or to last contact with the patient or anyfamily member. Kaplan–Meier method was used for theestimation of the OS and differences in survivals wereassessed using the log-rank test. A p value less than 0.05was accepted as statistically significant. Statisticalanalysis was carried out using SPSS 16.0 software (SPSSInc., Chicago, Illinois, USA).
3. ResultsBetween February 2010 and September 2013, 111 CRCpatients (female/male = 40/71) were included in thestudy. The baseline histopathological and thedemographic characteristics of the patients are listed inTable 1. Median (±SD) age and BMI of patiens were60±13 years and 24.7±4.8 kg/m2, respectively. Most ofthe patients (n = 103) had good ECOG performancescore (0-1). BMI was ≥30 kg/m2 in 21 patients.Metastatic disease was present in 57 (51.4%) patients.Among 54 early stage patients, 25 patients (46.3%) hadnode-positive disease. Treatment modalities andoutcomes of patients are summarized in Table 2. Fortypercent of 40 metastatic patients who received palliativesystemic therapy was responsive (partial or completeresponse).
Table 1: Patient and disease characteristics.Variables n (%)Number of patients 111(100)Gender Male 71 (64)Female 40 (36)Smoking status (+) 48 (43.2)(-) 53 (47.8)Unknown 10 (9)Type 2 DM (+) 17 (15.3)(-) 94 (84.7)HT (+) 31 (27.9)(-) 80 (72.1)IHD (+) 7 (6.3)(-) 104 (93.6)Stage of tumor I 1 (0.9)II 22 (19.8)III 31 (27.9)IV 57 (51.9)Location of tumor Right colon+hepaticflexura 24(21.6)Transvers colon 4 (3.6)Splenic flexura+leftcolon+sigmoid colon 28 (25.2)Rectosigmoidjunction 6 (5.4)Multiple synchronouscolon tumors 4 (3.6)Rectum 45 (40.5)Site of metastasis ¥ Liver 33 (57.8)Peritoneum 22 (38.5)Lung 11 (19.2)Bone 8 (14)Grade 1 10 (9)2 54 (48.6)3 8 (7.2)Unknown 39 (35.2)ALI (+) 38 (34.2)(-) 17 (15.3)Unknown 56 (50.5)VI (+) 16 (14.4)(-) 38 (34.3)Unknown 57 (51.3)PNI (+) 23 (20.7)(-) 34 (30.6)Unknown 54 (48.7)Regression score* 0-2 16(47)3-4 18(53)KRAS status¥ Mutant 15 (26.3)Wild 30 (52.7)Unknown 12 (21)CEA Normal (<5 ng/ml) 53 (47.7)High (>5 ng/ml) 22 (19.9)Unknown 36 (32.4)CA19.9 Normal (<38 U/ml) 62 (55.8)High (>38 U/ml) 13 (11.8)Unknown 36 (32.4)PS: Performance score; DM: Diabetes mellitus; HT:Hypertension; IHD: Ischemic heart disease; ALI:Angiolymphatic invasion; VI: Venous invasion; PNI:Perineural invasion
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Figure 1: Comparison of serum VCAM-1 levels in CRCpatients and controls. Figure 2: Comparison of serum VCAM-1 levels according tostage in CRC patients.
Table 2: Summary of treatment of patients and outcomes.Variables n (%)
Treatment of early stage diseaseNeoadjuvant CRT+adjuvant CT* 26 (23.4)Neoadjuvant short-term RT+adjuvantCT* 8 (7.2)Adjuvant CRT+CT* 7 (6.3)Adjuvant CT only 12(10.8)Observation after surgery 1(0.9)
Treatment of metastatic diseasePalliative treatments Palliative CT±targeted gents+BSC 40 (36)BSC alone 10 (9)Unknown 7 (6.3)CT regimens** FUFA/Capecitabine 3 (7.5)Irinotecan- based CT 15 (37.5)Oxaliplatin-based CT 21 (52.5)Targeted agents** Bevacizumab 22 (55)Cetuximab 13 (32.5)Response to systemic therapy** CR+PR 16 (40)SD+PD 18 (45)Unknown 6 (15)
OutcomesProgression (+) 18 (16.2)(-) 93 (83.2)Last status Exitus 20 (18)Alive with disease 37 (33.3)No evidence of disease 54 (48.6)*For rectum cancer only; **For 40 metastatic patient receiving systemic treatment; CT: Chemotherapy; CRT: Concurrentchemoradiotherapy; RT: Radioterapy; BSC: Best supportive care; CR: Complete response; PR: Partial response; SD: Stabildisease; PD: Progressive disease
Table 3: Comparison of serum VCAM1 levels of CRC patients and controls (median±SD).CRC group Control group pSerum VCAM1 level (ng/ml) 349.2±131.5 140.6±110.2 <0.001**Student's T test; CRC: Colorectal cancer
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Table 4: Results of comparisons between the median (±SD) values of serum VCAM1 and various clinical/pathologicalparameters.Variables VCAM1 level (ng/ml)(median±SD) pAge (years) <50 347.3±145.3 0.56≥50 349.5±128.1BMI (kg/m2) <30 354±140 0.34≥30 347.1±111.2Gender Male 359.4±124.5 0.42Female 346.3±143.8Smoking status (+) 372.8±136.1 0.7(-) 342.5±130.6Type 2 DM (+) 372.5±118 0.03(-) 346.3±131.3HT (+) 347.1±111.5 0.94(-) 349.3±139.1IHD (+) 318.1±98.2 0.6(-) 349.3±133.6Stage I 282.2 0.98*II 348.1±101.5III 386.5±134.1IV 333.5±142.9Tumor location Colon 354±136.2 0.61Rectum 338.2±125.9Liver metastasis (+) 342.5±145.5 0.8(-) 314.3±118.5Lung metastasis (+) 361.5±98.9 0.56(-) 323.1±144Bone metastasis (+) 339.8±105.1 0.8(-) 328.1±141.3Peritoneal metastasis (+) 310±146.3 0.86(-) 366.1±129.2Grade 1 409.8±108.2 0.12*2 358.9±130.93 286±105.4ALI (+) 348.1±131.2 0.16(-) 358.5±105.4VI (+) 357.6±115.4 0.52(-) 348.3±126.1PNI (+) 342.5±140.8 0.22(-) 352.8±112.7Regression score# 0-2 340.3±126.7 0.683-4 295±108.1KRAS status┼ Mutant 409.1±131.6 0.13Wild 313±140.3Response to systemictherapy┼ Responsive(CR+PR) 362.5±149.3 0.57Unresponsive(SD+PD) 389.6±151.8Progression (+) 369.3±136.5 0.25(-) 347.1±130.3Last status Exitus 355.5±120.9 0.82*Alive with disease 328.1±150.8No evidence ofdisease 363.8±122.8Student's T test; *One Way Anova test; ≠For 34 rectum cancer patients who received neoadjuvant therapy; ┼ For metastaticpatients; BMI: Body mass index; PS: Performance score; DM: Diabetes mellitus; HT: Hypertension; IHD: Ischemic heartdisease; ALI: Angiolymphatic invasion; VI: Venous invasion; PNI: Perineural invasion; CR: Complete response; PR: Partialresponse; SD: Stabil disease; PD: Progressive disease
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Table 5: Univariate analysis of overall survival.Variables No of events(death) Median OS(months±SE) 95% CI pAge (years) <50 2 22.2±1.1 19.8-24.5 0.11≥50 18 35.8±2 31.7-39.9BMI (kg/m2) <30 10 38.9±2 34.9-43 0.23≥30 5 35.4±4 26.6-42.4Gender Male 10 38.7±2.1 34.5-42.8 0.17Female 10 33.7±3 27.8-39.7Smoking status (+) 6 32.9±1.9 29.2-36.7 0.27(-) 12 35.4±2.6 30.2-40.6Type 2 DM (+) 4 18.9±1.7 15.5-22.3 0.59(-) 16 37.6±1.8 34-41.3HT (+) 7 19.7±1.6 16.4-23 0.26(-) 13 38.1±1.9 34.2-42IHD (+) 2 16.4±3.1 10.2-22.6 0.36(-) 18 37.5±1.8 33.9-41Metastasis (+) 19 31.7±2.6 26.5-36.9 <0.001(-) 1 43.6±1.3 40.9-46.2Tumor location Colon 14 34.9±2.3 30.9-39.5 0.29Rectum 6 39.3±2.5 34.3-44.2Response to systemictreatment* Responsive(CR+PR) 4 30.3±3.3 23.8-36.8 0.76Unresponsive(SD+PD) 5 34±4.5 25.1-42.9Grade 1 2 17.9±2.5 12.9-22.9 0.552 5 40.6±1.8 37-44.23 1 16±1.8 12.3-19.6ALI (+) 3 41.2±2 37.2-45.3 0.67(-) 2 17.8±0.2 16.4-19.2VI (+) 2 24.8±2 20.8-28.9 0.6(-) 3 40.6±2.3 35.9-45.3PNI (+) 3 33±2.6 27.7-38.2 0.33(-) 2 28.1±1.2 25.6-30.5KRAS status* Mutant 6 12.8±1.4 10.1-15.6 0.26Wild 7 36.2±3.2 29.9-42.5CEA Normal(<5ng/ml) 2 43±1.3 40.3-45.7 <0.001High(>5ng/ml) 9 16±1.7 12.5-19.4CA19.9 Normal(< 38U/ml) 7 39.9±1.8 36.4-43.5 0.08High(>38U/ml) 4 15.1±1.1 12.8-17.4Serum VCAM1 level < median 9 38.3±2.3 33.8-42.8 0.55≥ median 11 35.1±2.6 29.8-40.3Kaplan-Meier and log rank test; * For metastatic patients; OS: Overall survival; CI: Confidence interval; BMI: Body mass index;PS: Performance score; DM: Diabetes mellitus; HT: Hypertension; IHD: Ischemic heart disease; ALI: Angiolymphatic invasion;VI: Venous invasion; PNI: Perineural invasion; CR: Complete response; PR: Partial response; SD: Stabil disease; PD:Progressive disease; SE: Standart errorThe median serum VCAM1 level was significantly higherin CRC patients than controls (349.2 vs 140.6 ng/ml,
p<0.001) (Table 3; Figure 1). In addition, serum VCAM1level was significantly higher in diabetic CRC patientsthan those without diabetes (372.5 vs 346.3, p = 0.03).However, there was no significant relationship betweenVCAM1 and other clinicopathological parametersincluding stage and response to systemic therapy (Table4, Figure 2). Further analysis revealed that when
diabetic patients are excluded, serum VCAM1 is similarlyhigher in CRC patients (346.3±131.9 vs 140.6±110.2ng/ml, p<0.001) than controls regardless of the stage.The median follow-up period was 12 (±8.2) months.Twenty (18%) of patients were dead at the time ofanalysis. In univariate analysis, the presence ofmetastasis (31.7 vs 43.6 months, p<0.001) and elevatedCEA level (16 vs 43 months, p<0.001) were factors
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affecting OS significantly (Table 5). Neither serumVCAM1 level, nor the other clinicopathologicalparameters had a significant impact on OS in our study(Table 5; Figure 3). There were no significantcorrelations between serum VCAM1 level and CEA (Rho:-0.05, p = 0.64), CA19.9 (Rho: 0.11, p = 0.34) and BMI(Rho: -0.007, p = 0.95).
Figure 3: Kaplan-Meier curves according to VCAM-1 level.
4. DiscussionThe current study demonstrated that serum VCAM1level is elevated in CRC patients regardless of the diseasestage. Most of the previous studies have determined thecirculating VCAM1 level of CRC patients to be higherthan controls2,3, 11,13,23, which means that our results areconsistent with the literature. However, there is onlyone study suggesting that serum VCAM1 level is notelevated in CRC.20 This study excluded metastaticpatients and serum VCAM1 level was measuredpreoperatively, while we included both early stage andmetastatic patients and we analyzed serum VCAM1 levelpostoperatively for early stage patients.Endothelial VCAM1 expression is known to be inducedby VEGF, TNF-α, IL-1 and IFN-γ 5, although it is not wellknown whether these cytokines originate from thetumor cells or from the host cells surrounding thetumor.1,5 While the mechanism of passage of adhesionmolecules into the circulation is not known exactly, it isbelieved to occur after the adhesion of leukocytes ortumor cells to the endothelium.24 In cancer, circulatingVCAM1 may elevate due to increased production ofVCAM1 in cancerous tissue or cytokines secreted duringhost immun response against tumor.2,3,7,15 In fact, thesource of circulating adhesion molecules, theirmolecular characteristics and biological significance isnot known in detail.3 The most likely source is enzymaticdegradation of the adhesion molecules on the cellsurface. VCAM1 can be released into the circulation fromthe endothelial surface via ADAM (a disintegrin andmetalloprotease) 17, 8 and 9 enzymes.1 In addition,half-life of circulating VCAM1 is not known exactly.
TNF-α-induced VCAM1 expression on the cell surfacehas been shown that continued up to 4 hours25,suggesting that elevated VCAM1 level of patients aftersurgery is not related to long half-time of VCAM1 in ourstudy.Serum VCAM1 level may be influenced by a number offactors associated with endothelial activation, such astype 2 diabetes, atherosclerosis, asthma, rheumatoidarthritis and allergic events.1 We have shown that CRCpatients with diabetes have higher VCAM1 levelscompared to non-diabetics. However, our re-analysisexcluding the diabetic patients revealed that VCAM1elevation in CRC is regardless of diabetes. Shear-stress,reactive oxygen radicals, microbial agents, cytokines,oxide low-density lipoprotein, homosysteine,hyperglysemia, adipokines and nitric oxide arewell-known factors affecting VCAM1 expression duringendothelium activation.1 In our study, we could notmeasure all these factors which might have affected ourresults.Conflicting results were obtained from the studies on therelationship between blood VCAM1 levels and the stageof CRC.2,3,11,22,23 Moreover the studies suggesting thatVCAM1 level is associated with disease stage are veryheterogeneous. For example, one study (n = 46) includedearly stage and metastatic patients to only liver.23Another study measured VCAM1 level after surgery forearly stage (n = 91) but during CT for metastatic disease(n = 63) and concluded that VCAM1 level is positivelycorrelated with CRC stage, comparing rates of patientswith elevated VCAM1 level between early stage (33%)and metastatic disease (49%).11 Another studymeasured VCAM1 before surgery and concluded thatVCAM1 is higher in metastatic disease, however VCAM1level was not different according to stage innon-metastatic patients.2 Two other studies suggestedthat preoperative VCAM1 level is not associated withstage in early stage disease.3,22 In our study, wemeasured VCAM1 level of early stage patients aftersurgery and prior to CT for both early stage andmetastatic patients. Interestingly, VCAM1 level wassimilar in all stages, including even metastatic patients.Given that we could not find any association betweenVCAM1 and disease stage, our study seems consistentwith other studies revealing that VCAM1 is not differentbetween stages in non-metastatic CRC patients.2,3,22However, we do not agree with the studies suggestingthat VCAM1 level is much more higher in metastatic CRCpatients than those without metastasis.2,11,23Similar VCAM1 levels in patients with tumor burden andthose with no evidence of disease suggest that VCAM1may have different roles in early and late stages of CRC.Circulating VCAM1 produced by tumor may protecttumor cells from leukocytes, facilitate adhesion of tumorcells to endothelium of targeted metastasis site and theninduce angiogenesis and tumor progression. In contrast,
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VCAM1 of vessels surrounding the tumor may haveanti-tumor effects providing leukocyte adhesion tocancerous tissue.2,3,5 Unfortunately, current techniquescan not discriminate biological function of circulatingVCAM1 and whether its source is tumor cell orendothelium. Circulating VCAM1 is thought to have dualeffects on leukocytes by both inhibiting binding ofleukocytes to endothelium and inducing leukocytechemotaxis.1,5 Hypothetically, it can be suggested thatendothelial VCAM1 expression is initiated in order toincrease the immune response to the tumor, but then itcontributes to tumor growth and metastasis bystimulating angiogenesis.Correlation between VCAM1 and CEA has beenexamined in a few studies. One of these studiessuggested that preoperative VCAM1 level is positivelycorrelated with CEA and significantly decreases aftersurgery.2 However, we have found no correlationbetween BMI, CEA, CA19.9 and VCAM1, in accordancewith the two previous studies.3,20 Based on our results itcan be hypothesized that VCAM1 may reflect thevascular and inflammatory component of the tumorbetter, in contrast to CEA which reflects epithelial tumorload generally.5Few studies examined the role of VCAM1 level onsurvival of CRC patients and the results arecontradictory.2,11,20,21 Two of these studies suggestedthat VCAM1 level has no impact on survival, while theother two concluded that high VCAM1 level is associatedwith decreased OS.2,11,20,21 In addition, a prospectivestudy showed that preoperative high VCAM1 level isassociated with significantly increased recurrencerates.22 In our study, we could not find any relationshipbetween VCAM1 level and OS. Besides, we could notanalyze whether VCAM1 level is associated with relapserates or disease-free survival, because only one patientwith early stage disease had recurrence and only 20patients were dead at the time of analysis. Our follow-uptime was probably not long enough for survival analysis,therefore we were unable to indicate prognostic effect ofVCAM1 in CRC.Dynamic changes in VCAM1 level during systemictreatment of CRC were evaluated in two studies.13,21 Thefirst study revealed that an increase in the level of serumVCAM1 is associated with early relapse and poorprognosis.13 The second study included 38 metastaticCRC patients and indicated that VCAM1 levels increaseduring CT.21 One of the major limitations of our study isthat we could not evaluate neither serum VCAM1 levelchanges during systemic therapy, nor its significance forCT response and survival. However, none of the studiesin the literature have examined whether pretreatmentVCAM1 level is predictive for CT response. Our study isthe first study providing insight in this regard and weindicated that pretreatment serum VCAM1 level has nopredictive role for CT response.
5. ConclusionOur study has demonstrated that VCAM1 level iselevated in CRC patients compared to controls andinterestingly similar in patients with tumor burden andthose with no evidence of disease, suggesting thatVCAM1 may have different roles in early and late stagesof CRC. We could not find any association with VCAM1level and CT response or survival, probably due to shortfollow-up period. The real source or biological activity ofserum VCAM1 in CRC patients is not known exactly.Unfortunately, we could not measure the all knownendothelium activating factors which may affect ourresults and dynamic changes of VCAM1 level during CTin our study. Larger scale prospective studies whichinclude more homogeneous patient and treatmentgroups with longer follow-up are required to find outthe exact significance of serum VCAM1 level in CRC.
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